Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX)‘s stock had its “sector perform” rating reissued by investment analysts at Royal Bank Of Canada in a research report issued on Monday, StockTargetPrices.com reports. They currently have a C$39.00 target price on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price target suggests a potential upside of 69.86% from the stock’s current price.
VRX has been the topic of a number of other research reports. Scotiabank dropped their price target on shares of Valeant Pharmaceuticals Intl from C$34.00 to C$32.00 and set a “sector perform” rating on the stock in a research note on Tuesday, November 1st. TD Securities reiterated a “buy” rating and issued a C$38.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, August 10th.
Shares of Valeant Pharmaceuticals Intl (TSE:VRX) traded up 1.00% during trading on Monday, reaching $23.19. 295,470 shares of the company’s stock were exchanged. Valeant Pharmaceuticals Intl has a 12 month low of $18.41 and a 12 month high of $165.77. The stock has a 50-day moving average price of $26.49 and a 200 day moving average price of $31.56. The firm’s market cap is $8.06 billion.
About Valeant Pharmaceuticals Intl